Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2019) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 30 (2). p. 344. ISSN 0923-7534

Metadata

Authors/Creators:
  • Schöffski, P
  • Wozniak, A
  • Stacchiotti, S
  • Rutkowski, P
  • Blay, J-Y
  • Lindner, LH
  • Strauss, SJ
  • Anthoney, A
  • Duffaud, F
  • Richter, S
  • Grünwald, V
  • Leahy, MG
  • Reichardt, P
  • Sufliarsky, J
  • van der Graaf, WT
  • Sciot, R
  • Debiec-Rychter, M
  • van Cann, T
  • Marréaud, S
  • Lia, M
  • Raveloarivahy, T
  • Collette, L
  • Bauer, S
Commentary on: Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2017) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 28 (12). pp. 3000-3008. ISSN 0923-7534
Dates:
  • Published: 1 February 2019
  • Accepted: 18 September 2017
  • Published (online): 5 May 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 31 Oct 2019 09:39
Last Modified: 31 Oct 2019 09:39
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdx823
Related URLs:

Commentary/Response Threads

Download

Share / Export

Statistics